|Posted on 12/10/2015 3:26:00 AM.|
A pharmaceutical company out of Baton Rouge has created a therapeutic vaccine for prostate cancer. Phase one of the therapy vaccine, ProscaVax, developed by OncBioMune Pharmaceuticals Inc, has been approved by the FDA. CEO Jonathan Head says there is a huge need for this product and so far in trials it’s been a success with very little side effects.
|OncBioMune, ProscaVax, Jonathan Head, prostate cancer, vaccine, FDA|